anurajms/meta_analysis huggingface dataset:
comparison group:
Interventions for unexplained infertility: a systematic review and network meta‐analysis
1. In Vitro Fertilization 2. Intracytoplasmic sperm injection 3. Timed sexual intercourse 4. Intrauterine Insemination 5. Expectant Management 6. Gonadotropins And Other Ovulation Stimulants
comparison group:
Time‐lapse systems for embryo incubation and assessment in assisted reproduction
1. Usual Care
comparison group:
Strategies to improve adherence and continuation of shorter‐term hormonal methods of contraception
1. Usual Care
comparison group:
Interventions using social networking sites to promote contraception in women of reproductive age
1. Usual Care
comparison group:
Interventions for emergency contraception
1. Copper intrauterine device 2. Placebo 3. Emergency Contraceptives
comparison group:
Inositol for subfertile women with polycystic ovary syndrome
1. Inositol 2. Placebo 3. Oral 4. Usual Care
comparison group:
Hysteroscopy for treating subfertility associated with suspected major uterine cavity abnormalities
1. Diagnostic Hysteroscopy
comparison group:
Penile rehabilitation for postprostatectomy erectile dysfunction
1. Erectile Dysfunction Vacuum Therapy System 2. Phosphodiesterase 5 Inhibitors 3. Placebo 4. Alprostadil 5. Penile Vacuum Constriction Device
comparison group:
Intrauterine administration of human chorionic gonadotropin (hCG) for subfertile women undergoing assisted reproduction
1. Placebo 2. Usual Care
comparison group:
Vasodilators for women undergoing fertility treatment
1. Placebo 2. Usual Care
comparison group:
Pain relief for women undergoing oocyte retrieval for assisted reproduction
1. Spinal Anesthesia 2. Paracervical Block Anesthesia 3. Patient Controlled Analgesia 4. Placebo 5. General Anesthesia 6. Acupuncture 7. Sedation
comparison group:
Application of seminal plasma to female genital tract prior to embryo transfer in assisted reproductive technology cycles (IVF, ICSI and frozen embryo transfer)
1. Usual Care
comparison group:
Anti‐adhesion therapy following operative hysteroscopy for treatment of female subfertility
1. Anti-adhesion therapy 2. Allograft Of Amniotic Membrane 3. Hyaluronic Acid 4. Intrauterine Device 5. Placebo 6. Intrauterine Balloon 7. Carboxymethylcellulose 8. Hormone Therapy
comparison group:
Oral medications including clomiphene citrate or aromatase inhibitors with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilisation
1. Gonadotropins
comparison group:
Pain relief for outpatient hysteroscopy
1. Analgesics 2. Placebo
comparison group:
Cycle regimens for frozen‐thawed embryo transfer
1. Gonadotropins And Other Ovulation Stimulants 2. Hormone Therapy
comparison group:
Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles
1. Recombinant Follicle Stimulating Hormone
comparison group:
Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome
1. Gonadotropin Releasing Hormone Agonist 2. Early Treatment 3. Gonadotropin releasing hormone antagonist 4. Oocyte retrieval 5. Follicular Aspiration 6. Cabergoline
comparison group:
Septum resection for women of reproductive age with a septate uterus
1. Expectant Management
comparison group:
Clomiphene and other antioestrogens for ovulation induction in polycystic ovarian syndrome
1. Corticosteroids - Otological 2. Placebo 3. Gonadotropins 4. Anti-estrogens 5. Tamoxifen 6. Clomiphene Citrate 7. Dopamine Agonists
comparison group:
Day three versus day two embryo transfer following in vitro fertilization or intracytoplasmic sperm injection
1. Day Three Embryo Transfer
comparison group:
Human chorionic gonadotrophin priming for fertility treatment with in vitro maturation
1. Placebo 2. Human Chorionic Gonadotropin
comparison group:
Aspirin for in vitro fertilisation
1. Placebo
comparison group:
Volume expanders for the prevention of ovarian hyperstimulation syndrome
1. Placebo
comparison group:
Progestin‐only contraceptives: effects on weight
1. Placebo
comparison group:
Hormonal contraceptives for contraception in overweight or obese women
1. Hormonal Contraceptives For Systemic Use 2. Vaginal Ring With Progestogen And Estrogen 3. Drug-eluting Contraceptive Implant 4. Administration Of Depot Contraceptive 5. Ethinyl Estradiol / Etonogestrel Vaginal Ring 6. Injection Of Medroxyprogesterone Acetate 7. Drug-eluting Intrauterine Device
comparison group:
Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology
1. Gonadotropin Releasing Hormone Agonist
comparison group:
Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles
1. Urinary Human Chroionic Gonadotropin
comparison group:
Psychological and educational interventions for subfertile men and women
1. Usual Care 2. Waiting list control 3. Attention Placebo Control
comparison group:
Brief educational strategies for improving contraception use in young people
1. Usual Care
comparison group:
Ultrasound versus 'clinical touch' for catheter guidance during embryo transfer in women
1. Usual Care
comparison group:
Assisted reproductive technologies for male subfertility
1. Intrauterine Insemination with Ovarian Stimulation Using Partner Sperm 2. In Vitro Fertilization 3. Timed sexual intercourse 4. Intrauterine Insemination 5. Expectant Management
comparison group:
Culture media for human pre‐implantation embryos in assisted reproductive technology cycles
1. Embryo transfer media
comparison group:
Gonadotrophin‐releasing hormone agonist protocols for pituitary suppression in assisted reproduction
1. Length of Procedure
comparison group:
Lactational amenorrhoea method for family planning
1. Breastfeeding
comparison group:
Pain relief in hysterosalpingography
1. Analgesics 2. Placebo
comparison group:
Luteal phase support for assisted reproduction cycles
1. Gonadotropin Releasing Hormone Agonist 2. Progesterone And Estrogen 3. Human chorionic gonadotropin 4. Progesterone
comparison group:
Ovarian cyst aspiration prior to in vitro fertilization treatment for subfertility
1. Conservative Therapy
comparison group:
Gonadotropin‐releasing hormone agonist versus HCG for oocyte triggering in antagonist‐assisted reproductive technology
1. Human chorionic gonadotropin
comparison group:
Vitrification versus slow freezing for women undergoing oocyte cryopreservation
1. Slow freezing
comparison group:
Surgical intervention versus expectant management for endometrial polyps in subfertile women
1. Expectant Management
comparison group:
Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus
1. Hormonal Contraceptives For Systemic Use 2. Placebo
comparison group:
Oral contraceptives for functional ovarian cysts
1. Hormonal Contraceptives For Systemic Use 2. Placebo 3. Danazol
comparison group:
Combination contraceptives: effects on weight
1. Progestogens And Estrogens Systemic Contraceptives, Sequential Preparations 2. Placebo 3. Progestogens And Estrogen Systemic Contraceptives, Fixed Combinations
comparison group:
Heparin for assisted reproduction
1. Aspirin 2. Placebo 3. Heparin 4. Low Molecular Weight Heparin
comparison group:
Exercise as adjunctive therapy for systemic lupus erythematosus
1. Alternative therapy 2. Usual Care
comparison group:
Adjunctive therapies in addition to land‐based exercise therapy for osteoarthritis of the hip or knee
1. Sham Intervention 2. Exercise
comparison group:
Stem cell transplantation for systemic sclerosis
1. Cyclophosphamide 2. Immunomodulators
comparison group:
Dietary supplements for chronic gout
1. Pharmacotherapy 2. Diet Education 3. Placebo 4. Nutrient supplementation
comparison group:
Autologous blood and platelet‐rich plasma injection therapy for lateral elbow pain
1. Exercise therapy 2. Placebo 3. Drug Therapy
comparison group:
Colchicine for acute gout
1. Drug Therapy 2. Placebo
comparison group:
Tramadol for osteoarthritis
1. Placebo
comparison group:
Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in patients with low disease activity
1. Tumor Necrosis Factor Alpha Inhibitors 2. Usual Care
comparison group:
Methotrexate for psoriatic arthritis
1. Non-steroidal Anti-inflammatory Drug 2. Disease-Modifying Antirheumatic Drug 3. Analgesics 4. Placebo
comparison group:
Exercise for rheumatoid arthritis of the hand
1. Physiotherapy 2. Placebo 3. Usual Care 4. Operative Procedure On Hand
comparison group:
Exercise interventions and patient beliefs for people with hip, knee or hip and knee osteoarthritis: a mixed methods review
1. Waiting list control
comparison group:
Surgery for trigger finger
1. Splinting Of Finger 2. Corticosteroids - Otological 3. Placebo 4. Physiotherapy 5. Procedure On Finger 6. Infiltration 7. Usual Care
comparison group:
Back Schools for chronic non‐specific low back pain
1. Physiotherapy 2. Exercise therapy
comparison group:
Celecoxib for rheumatoid arthritis
1. Non-steroidal Anti-inflammatory Drug 2. Placebo
comparison group:
Celecoxib for osteoarthritis
1. Non-steroidal Anti-inflammatory Drug 2. Placebo
comparison group:
Exercise for hand osteoarthritis
1. Sham Intervention 2. Hand Exercises 3. Usual Care 4. Waiting list control
comparison group:
Stretch for the treatment and prevention of contractures
1. Sham Intervention 2. Placebo 3. Usual Care
comparison group:
Surgical options for lumbar spinal stenosis
1. Placebo 2. Sham Surgery
comparison group:
Bioabsorbable versus metallic interference screws for graft fixation in anterior cruciate ligament reconstruction
1. Anterior cruciate ligament reconstruction 2. Internal Orthopaedic Fixation System, Plate/screw, Non-bioabsorbable
comparison group:
Electrotherapy modalities for rotator cuff disease
1. Low Power Laser Therapy 2. Phonophoresis Therapy 3. Interferential Therapy 4. Ultrasound therapy 5. Transcutaneous Electrical Nerve Stimulation 6. Electrotherapy 7. Placebo 8. Short Wave Diathermy 9. Pulsed Electromagnetic Energy Therapy 10. Iontophoresis Procedure 11. Electromyographic Biofeedback
comparison group:
Biologic interventions for fatigue in rheumatoid arthritis
1. Placebo 2. Usual Care
comparison group:
Non‐steroidal anti‐inflammatory drugs for chronic low back pain
1. Placebo
comparison group:
Surgery for Dupuytren's contracture of the fingers
1. Sham Intervention 2. Surgery 3. Physiotherapy 4. Placebo 5. Collagenase 6. Radiotherapy 7. Hand Therapy
comparison group:
High‐intensity versus low‐intensity physical activity or exercise in people with hip or knee osteoarthritis
1. Low Intensity Exercise
comparison group:
Radiofrequency denervation for chronic low back pain
1. Placebo
comparison group:
Intra‐articular corticosteroid for knee osteoarthritis
1. Sham Intervention
comparison group:
Non‐steroidal anti‐inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non‐radiographic axial spondyloarthritis)
1. Non-steroidal Anti-inflammatory Drug 2. Placebo
comparison group:
TNF‐alpha inhibitors for ankylosing spondylitis
1. Placebo 2. Usual Care
comparison group:
Mobile bearing vs fixed bearing prostheses for posterior cruciate retaining total knee arthroplasty for postoperative functional status in patients with osteoarthritis and rheumatoid arthritis
1. Implantable Knee Prosthesis 2. Knee replacement
comparison group:
Rituximab for rheumatoid arthritis
1. Disease-Modifying Antirheumatic Drug 2. Placebo
comparison group:
Exercise for osteoarthritis of the knee
1. Usual Care 2. Waiting list control
comparison group:
Sulfasalazine for ankylosing spondylitis
1. Placebo
comparison group:
Uricosuric medications for chronic gout
1. Non-Pharmacological Interventions 2. Febuxostat 3. Allopurinol 4. Placebo 5. Uricosuric agent
comparison group:
Electrotherapy modalities for adhesive capsulitis (frozen shoulder)
1. Electrotherapy 2. Placebo
comparison group:
Interleukin‐1 inhibitors for acute gout
1. Pharmacotherapy 2. Placebo 3. Interleukin Inhibitors
comparison group:
Manual therapy and exercise for adhesive capsulitis (frozen shoulder)
1. Placebo 2. Shoulder Exercises 3. Manual Therapy
comparison group:
Diacerein for osteoarthritis
1. Placebo
comparison group:
Self‐management education programmes for osteoarthritis
1. Usual Care 2. Waiting list control 3. Written information provision
comparison group:
Rehabilitation following surgery for lumbar spinal stenosis
1. Usual Care
comparison group:
Lifestyle interventions for acute gout
1. Pharmacotherapy 2. Placebo
comparison group:
Non‐pharmacological interventions for fatigue in rheumatoid arthritis
1. Non-Pharmacological Interventions 2. Placebo 3. Usual Care
comparison group:
Erythropoiesis‐stimulating agents for anemia in rheumatoid arthritis
1. Folic Acid 2. Darbepoetin Alfa 3. Placebo 4. Iron Preparations 5. Red Blood Cell Transfusion 6. Epoetin Alfa 7. Usual Care 8. Epoetin Beta
comparison group:
Treatments for alopecia areata: a network meta‐analysis
1. Drug vehicle 2. Placebo
comparison group:
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis
1. Brodalumab 2. Certolizumab Pegol 3. Fumaric Acid 4. Ustekinumab 5. Secukinumab 6. Ixekizumab 7. Netakimab 8. Acitretin 9. Infliximab 10. Etanercept 11. Skin Care: Topical Treatments 12. Apremilast 13. Ciclosporin 14. Methotrexate 15. Adalimumab 16. Tildrakizumab 17. Risankizumab 18. Guselkumab 19. Phototherapy Of Skin
comparison group:
Negative pressure wound therapy for treating pressure ulcers
1. Negative Pressure Wound Dressing
comparison group:
Silicone gel sheeting for treating keloid scars
1. Silicone Gel Sheet Dressing 2. Placebo
comparison group:
Dressings and topical agents for the management of open wounds after surgical treatment for sacrococcygeal pilonidal sinus
1. Skin Care: Topical Treatments 2. Wound dressing
comparison group:
Pressure redistributing static chairs for preventing pressure ulcers
1. Chair
comparison group:
Silicone gel sheeting for treating hypertrophic scars
1. Placebo
comparison group:
Botulinum toxin type A for facial wrinkles
1. Hyaluronic Acid 2. Placebo 3. Topical 4. Skin Fillers And Protectives
comparison group:
Topical benzoyl peroxide for acne
1. Placebo 2. Topical
comparison group:
Hygiene and emollient interventions for maintaining skin integrity in older people in hospital and residential care settings
1. Placebo 2. Usual Care
comparison group:
Interventions for chronic palmoplantar pustulosis
1. Placebo
comparison group:
Topical and device‐based treatments for fungal infections of the toenails
1. Placebo
comparison group:
Lifestyle changes for treating psoriasis
1. Usual Care
comparison group:
Interventions for hand eczema
1. Betamethasone Dipropionate 2. Mometasone furoate 3. Administration Of Drug Or Medicament To Skin Via Topical Route 4. Alitretinoin 5. Tacrolimus 6. Narrowband Ultraviolet B Phototherapy 7. Placebo 8. Oral 9. Cyclosporine 10. Photochemotherapy
comparison group:
Non‐antistreptococcal interventions for acute guttate psoriasis or an acute guttate flare of chronic psoriasis
1. Placebo
comparison group:
Antistreptococcal interventions for guttate and chronic plaque psoriasis
1. Placebo
comparison group:
Risk assessment tools for the prevention of pressure ulcers
1. Pressure Ulcer Risk Assessment 2. Usual Care
comparison group:
Support surfaces for treating pressure ulcers
1. Usual Care
comparison group:
Education of healthcare professionals for preventing pressure ulcers
1. Preventive 2. Pressure Ulcer Prevention Education 3. Usual Care
comparison group:
Foam dressings for treating pressure ulcers
1. Dressing Of Pressure Ulcer 2. Medical Dressing 3. Foam Dressing 4. Wound And Ulcer Preparations
comparison group:
Systemic antibiotics for treating malignant wounds
1. Placebo
comparison group:
Anabolic steroids for treating pressure ulcers
1. Pressure Ulcer Care Management 2. Anabolic Steroids 3. Placebo
comparison group:
Scalpel versus electrosurgery for major abdominal incisions
1. Scalpel
comparison group:
Drugs for discoid lupus erythematosus
1. Parenteral 2. Placebo 3. Topical 4. Oral
comparison group:
Emollients and moisturisers for eczema
1. Moisturizer application 2. Placebo 3. Emollient 4. Application Of Emollient To Skin
comparison group:
Wound drainage for lower limb arterial surgery
1. Post-surgical Wound Care
comparison group:
Bed rest for pressure ulcer healing in wheelchair users
1. Usual Care
comparison group:
Antibiotics and antiseptics for pressure ulcers
1. Antiseptics And Disinfectants 2. Antibacterials For Systemic Use 3. Antiseptics 4. Placebo 5. Usual Care 6. Antibiotics For Topical Use
comparison group:
Interventions for acne scars
1. Placebo
comparison group:
Antibiotics and antiseptics for surgical wounds healing by secondary intention
1. Antiseptics And Disinfectants 2. Antibacterials For Systemic Use 3. Antiseptics 4. Placebo 5. Usual Care 6. Antibiotics For Topical Use
comparison group:
Surgical hand antisepsis to reduce surgical site infection
1. Antiseptics And Disinfectants 2. Antiseptics 3. Placebo
comparison group:
Anti‐TNF agents for paediatric psoriasis
1. Placebo 2. Usual Care
comparison group:
Interventions for hidradenitis suppurativa
1. Placebo
comparison group:
Wound‐care teams for preventing and treating pressure ulcers
1. Pressure Ulcer Care Management 2. Preventive 3. Healthcare Professional 4. Healthcare Facility
comparison group:
Oral fumaric acid esters for psoriasis
1. Placebo
comparison group:
Negative pressure wound therapy for treating surgical wounds healing by secondary intention
1. Negative Pressure Wound Dressing
comparison group:
Interventions for rosacea
1. Placebo
comparison group:
Preoperative skin antiseptics for preventing surgical wound infections after clean surgery
1. Antiseptics And Disinfectants 2. Antiseptics
comparison group:
Interventions for vitiligo
1. Placebo
comparison group:
Repositioning for treating pressure ulcers
1. Repositioning
comparison group:
Negative pressure wound therapy for partial‐thickness burns
1. Wound Care
comparison group:
Recombinant human growth hormone for treating burns and donor sites
1. Drug Therapy 2. Placebo
comparison group:
Removal of nail polish and finger rings to prevent surgical infection
1. Nail polish application 2. Wearing finger ring
comparison group:
Topical agents and dressings for fungating wounds
1. Placebo
comparison group:
Pressure‐relieving devices for treating heel pressure ulcers
1. Pressure Relief Equipment 2. Usual Care
comparison group:
Narrow‐band ultraviolet B phototherapy versus broad‐band ultraviolet B or psoralen‐ultraviolet A photochemotherapy for psoriasis
1. Broadband ultraviolet B radiation 2. Photochemotherapy With Psoralens And Ultraviolet A
comparison group:
Antibiotic prophylaxis for preventing burn wound infection
1. Non-Pharmacological Interventions 2. Placebo 3. Antibiotic Prophylaxis 4. Usual Care
comparison group:
Psychosocial and pharmacologic interventions to reduce harmful alcohol use in low‐ and middle‐income countries
1. Lower Middle Income Country 2. Low Income Country
comparison group:
Baclofen for alcohol use disorder
1. Placebo
comparison group:
Opioid agonist treatment for people who are dependent on pharmaceutical opioids
1. Placebo 2. Psychotherapy 3. Detoxification Therapy
comparison group:
Music therapy for people with substance use disorders
1. Usual Care
comparison group:
Strategies to improve smoking cessation rates in primary care
1. Usual Care
comparison group:
Interventions to reduce tobacco use in people experiencing homelessness
1. Usual Care
comparison group:
Dihydrocodeine for detoxification and maintenance treatment in individuals with opiate use disorders
1. Placebo
comparison group:
Smoking cessation intervention for reducing disease activity in chronic autoimmune inflammatory joint diseases
1. Placebo 2. Usual Care 3. Written information about smoking cessation
comparison group:
Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation
1. Usual Care
comparison group:
Cognitive‐behavioural treatment for amphetamine‐type stimulants (ATS)‐use disorders
1. Psychotherapy 2. Support Group Facilitation
comparison group:
Antidepressants for the treatment of people with co‐occurring depression and alcohol dependence
1. Placebo
comparison group:
Effectiveness of brief alcohol interventions in primary care populations
1. Educational Material 2. Alcohol Consumption Screening 3. Usual Care
comparison group:
Personalised digital interventions for reducing hazardous and harmful alcohol consumption in community‐dwelling populations
1. Provision Of Written Information About Alcohol 2. Alcohol Consumption Screening
comparison group:
Opioid antagonists with minimal sedation for opioid withdrawal
1. Placebo
comparison group:
Supervised dosing with a long‐acting opioid medication in the management of opioid dependence
1. Buprenorphine 2. Methadone
comparison group:
Psychostimulant drugs for cocaine dependence
1. Placebo
comparison group:
Psychosocial interventions for cannabis use disorder
1. Psychotherapy 2. Complementary Therapy 3. Behavioral Therapy
comparison group:
Alpha2‐adrenergic agonists for the management of opioid withdrawal
1. Placebo
comparison group:
Antipsychotic medications for cocaine dependence
1. Placebo
comparison group:
Dopamine agonists for the treatment of cocaine dependence
1. Placebo
comparison group:
Anticonvulsants for cocaine dependence
1. Placebo 2. Usual Care
comparison group:
Universal school‐based prevention for illicit drug use
1. School 2. Substance Use Prevention 3. Substance Use Education
comparison group:
Restricting or banning alcohol advertising to reduce alcohol consumption in adults and adolescents
1. Advertising
comparison group:
Maintenance treatments for opiate ‐dependent adolescents
1. Detoxification Therapy 2. Psychosocial Care 3. Opiate agonist
comparison group:
Anticonvulsants for alcohol dependence
1. Psychosocial intervention 2. Drug Therapy 3. Placebo
comparison group:
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
1. Buprenorphine 2. Placebo 3. Methadone 4. Maintenance Therapy
comparison group:
Efficacy of psychostimulant drugs for amphetamine abuse or dependence
1. Placebo 2. Psychotherapy
comparison group:
Bladder training for treating overactive bladder in adults
1. Anticholinergics 2. Pelvic Floor Muscle Exerciser 3. Placebo 4. Beta-adrenoceptor agonist
comparison group:
Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women
1. Vaginal pessary 2. Pelvic Floor Exercises 3. Placebo 4. Pelvic Organ Prolapse Surgical Mesh
comparison group:
Conservative interventions for managing urinary incontinence after prostate surgery
1. Pelvic Floor Exercises 2. Sham Intervention 3. Provider Instructions For Treatment
comparison group:
Transurethral microwave thermotherapy for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
1. Sham Intervention 2. Connective Radiofrequency Water Vapour Thermal Therapy 3. Prostatic arterial embolization 4. Prostatic urethral lift procedure 5. Temporary Implantable Nitinol Device 6. Transurethral Prostatectomy
comparison group:
Anticholinergics combined with alpha‐blockers for treating lower urinary tract symptoms related to benign prostatic obstruction
1. Placebo
comparison group:
Convective radiofrequency water vapour thermal therapy for lower urinary tract symptoms in men with benign prostatic hyperplasia
1. Sham Intervention 2. Usual Care
comparison group:
Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction
1. Transurethral Prostatectomy
comparison group:
Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
1. Sham Intervention 2. Laser Ablation Of Prostate 3. Prostatectomy 4. Usual Care 5. Laser Enucleation Of The Prostate 6. Transurethral Prostatectomy
comparison group:
Physical activity for lower urinary tract symptoms secondary to benign prostatic obstruction
1. Sham Intervention 2. Constant Observation 3. Usual Care
comparison group:
Antimicrobial agents for preventing urinary tract infections in adults undergoing cystoscopy
1. Preventive 2. Placebo
comparison group:
Ureteral stent versus no ureteral stent for ureteroscopy in the management of renal and ureteral calculi
1. Ureteroscopy
comparison group:
Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia
1. Placebo 2. Usual Care
comparison group:
Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
1. Anticholinergics 2. Testosterone-5-alpha Reductase Inhibitors 3. Placebo 4. Phytosterols 5. Alpha-adrenergic blocking agent
comparison group:
Non‐pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome
1. Sham Intervention 2. Non-Pharmacological Interventions 3. Placebo
comparison group:
Electrical stimulation with non‐implanted devices for stress urinary incontinence in women
1. Transcutaneous Electrical Nerve Stimulation 2. Placebo 3. Non-Surgical Interventions 4. Sham Electrical Stimulation
comparison group:
Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
1. Testosterone-5-alpha Reductase Inhibitors 2. Placebo 3. Alpha-adrenoreceptor Antagonists
comparison group:
Desmopressin for treating nocturia in men
1. Placebo
comparison group:
Surgery versus non‐surgical management for unilateral ureteric‐pelvic junction obstruction in newborns and infants less than two years of age
1. Antibiotic Prophylaxis 2. Non-Surgical Interventions
comparison group:
Antimicrobial therapy for chronic bacterial prostatitis
1. Placebo 2. Antibiotic Therapy
comparison group:
Reconstructive surgery for treating pressure ulcers
1. Reconstruction Of Pressure Ulcer
comparison group:
Timing of antibiotic administration, wound debridement, and the stages of reconstructive surgery for open long bone fractures of the upper and lower limbs
1. Reconstruction Of Lower Limb 2. Skeletal Fixation Procedure 3. Reconstruction Of Upper Limb 4. Reconstruction Procedure 5. Soft Tissue Closure 6. Delayed Treatment 7. Staging 8. Administration Of Antibiotic 9. Surgical Debridement Of Wound 10. Debridement Of Open Fracture 11. Antibiotic Prophylaxis 12. Skin Flap Operation
comparison group:
Reactive air surfaces for preventing pressure ulcers
1. Gel-filled Bed Mattress 2. Water Mattress 3. Air-filled Mattress 4. Sheepskin bed mattress overlay 5. Fibre-filled Mattress
comparison group:
Intracavity lavage and wound irrigation for prevention of surgical site infection
1. Intracavity Lavage 2. Wound irrigation
comparison group:
Topical phenytoin for treating pressure ulcers
1. Pressure Ulcer Care Management 2. Dressing Of Pressure Ulcer 3. Medical Dressing 4. Placebo
comparison group:
Interventions for treating gas gangrene
1. Debridement 2. Antibacterials For Systemic Use 3. Ozone Therapy 4. Support System Interventions 5. Wound irrigation 6. Gas gangrene antitoxin 7. Traditional Chinese Medicine 8. Hyperbaric Oxygen Therapy
comparison group:
Dressings and securement devices for central venous catheters (CVC)
1. Gauze Dressing 2. Hydrocolloid Dressing 3. Adhesive Tape 4. Medicated Dressing 5. Polyurethane Foam Dressing 6. Securing Of Medical Device Tubing 7. Chlorhexidine 8. Suture
comparison group:
Devices and dressings to secure peripheral venous catheters to prevent complications
1. Bandage 2. Adhesive Tape 3. Bandages and surgical tapes
comparison group:
Perioperative corticosteroids for preventing complications following facial plastic surgery
1. Placebo
comparison group:
Continuous versus interrupted skin sutures for non‐obstetric surgery
1. Interrupted Suture Technique
comparison group:
Pin site care for preventing infections associated with external bone fixators and pins
1. Gauze Dressing 2. Primary Dressing 3. Foam Dressing
comparison group:
Systemic antimicrobial prophylaxis for percutaneous endoscopic gastrostomy
1. Placebo 2. Usual Care
outcomes:
Skin care interventions in infants for preventing eczema and food allergy
1. Eczema 2. Food Allergy
outcomes:
Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis
1. Forced Expiratory Volume 1 2. Forced Vital Capacity 3. Allergic Bronchopulmonary Aspergillosis 4. Cystic Fibrosis Pulmonary Exacerbation 5. Quality of Life 6. Wheezing 7. Adverse Event 8. Time-to-Event 9. Clinical Improvement 10. Reduction Of Corticosteroid Dosage
outcomes:
Anti‐IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis
1. Serious Adverse Event 2. Corticosteroids - Otological 3. Adverse Event 4. Therapeutic Response
outcomes:
Whole‐cell pertussis vaccine in early infancy for the prevention of allergy in children
1. Serious Adverse Event 2. IgE mediated Allergic Disorder 3. IgE-mediated food allergy
outcomes:
High versus low medium chain triglyceride content of formula for promoting short‐term growth of preterm infants
1. Growth 2. Feeding intolerance 3. Gastrointestinal Irritation 4. Head Circumference 5. Necrotizing Enterocolitis 6. Weight Gain 7. Height and growth measurements 8. Skinfold Measurement 9. Neurodevelopmental Delay
outcomes:
Sublingual immunotherapy for asthma
1. Pulmonary Methacholine Challenge Test 2. Serious Adverse Event 3. Corticosteroids - Inhaled 4. Quality of Life 5. Hospitalization 6. Adverse Event 7. Asthma exacerbation
outcomes:
Dilute versus full‐strength formula in exclusively formula‐fed preterm or low birth weight infants
1. Abdominal Distension 2. Infection 3. All Cause Mortality 4. Nutrient Intake 5. Gastric Residuals 6. Necrotizing Enterocolitis 7. Enteral Feeding Intolerance
outcomes:
Probiotics for treating eczema
1. Gastrointestinal Symptom 2. Eczema 3. Parent-Reported Outcome 4. Severity Scoring of Atopic Dermatitis Index 5. Patient-Reported Outcome
outcomes:
Infant formulas containing hydrolysed protein for prevention of allergic disease
1. Atopic Dermatitis 2. Eczema 3. Allergic Rhinitis 4. Cow's Milk Allergy 5. Food Allergy 6. Allergies 7. Asthma
outcomes:
Oral and sublingual immunotherapy for egg allergy
1. Serious Adverse Event 2. Clinical Cure 3. Adverse Event 4. Immunological tolerance 5. Tolerance Related Finding
outcomes:
Polyunsaturated fatty acid supplementation in infancy for the prevention of allergy
1. Rhinitis 2. Eczema 3. Food Allergy 4. Dermatitis 5. Allergies 6. Asthma
outcomes:
Specific allergen immunotherapy for the treatment of atopic eczema
1. Skin Reaction 2. Adverse Event
outcomes:
Leukoreduction for the prevention of adverse reactions from allogeneic blood transfusion
1. Infection 2. All Cause Mortality 3. Transfusion Related Acute Lung Injury 4. Transfusion Reaction
outcomes:
Immunotherapy (oral and sublingual) for food allergy to fruits
1. Immunological tolerance 2. Adverse Event
outcomes:
Glycerin laxatives for prevention or treatment of feeding intolerance in very low birth weight infants
1. Enteral nutrition 2. Infant Feeding Method
outcomes:
Maternal prenatal and/or postnatal n‐3 long chain polyunsaturated fatty acids (LCPUFA) supplementation for preventing allergies in early childhood
1. Allergies
outcomes:
H1‐antihistamines for chronic spontaneous urticaria
1. Withdrawn From Research Study 2. Suppression 3. Therapeutic Response
outcomes:
Omalizumab for asthma in adults and children
1. Medication Dose Decreased 2. Quality of Life 3. Lung function test 4. Asthma exacerbation 5. Adverse Event
outcomes:
Prebiotics in infants for prevention of allergy
1. Rhinitis 2. Eczema 3. Allergic Respiratory Disease 4. Food Allergy 5. Asthma
outcomes:
Lactase treated feeds to promote growth and feeding tolerance in preterm infants
1. Enteral nutrition 2. Normal Growth 3. Head Circumference 4. Weight Gain 5. Height and growth measurements
outcomes:
Oral H1 antihistamines as monotherapy for eczema
1. Eczema 2. Severity Scoring of Atopic Dermatitis Index 3. Itching
outcomes:
Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion‐dependent beta thalassaemia
1. Exercise Tolerance Test 2. Ferritin level 3. Echocardiography 4. Cardiac Assessment 5. Iron 6. Liver Finding 7. Adverse Event 8. Time-to-Event 9. Ventricular Filling Pressure Increased 10. Cardiac Function Testing 11. Atrial Natriuretic Factor Measurement 12. Cardiac Death 13. Left Ventricular Ejection Fraction
outcomes:
Topical repellents for malaria prevention
1. Malaria 2. Parasitemia
outcomes:
Interventions for chronic kidney disease in people with sickle cell disease
1. Kidney disease 2. Transfusion Related Complications 3. Transfusion Associated Circulatory Overload 4. Stroke 5. Glomerular Filtration Rate 6. Neutropenic Sepsis 7. Hospitalization 8. Acute Chest Syndrome 9. Haemolytic Reaction 10. Adverse Event 11. End Stage Kidney Disease 12. Adverse Drug Reaction 13. Disease Progression 14. Transfusion Related Acute Lung Injury 15. Quality of Life 16. Death 17. Complication 18. Urine Osmolarity 19. Hemoglobin SS Disease 20. Proteinuria 21. Pain Crisis
outcomes:
Rapamycin and rapalogs for tuberous sclerosis complex
1. Forced Expiratory Volume 1 2. Fibrous Skin Tumor Of Tuberous Sclerosis 3. Skin Lesion 4. Seizure 5. Withdrawal Due To Adverse Events 6. Adverse Event 7. Creatinine level 8. Therapeutic Response
outcomes:
Polyclonal anti‐thymocyte globulins for the prophylaxis of graft‐versus‐host disease after allogeneic stem cell or bone marrow transplantation in adults
1. Survival 2. Graft Versus Host Disease
outcomes:
Treatment for osteoporosis in people with beta‐thalassaemia
1. Bone Density 2. Fracture
outcomes:
Treatment of dental and orthodontic complications in thalassaemia
1. Oral Cavity Finding 2. Malocclusion 3. Clinical Resolution 4. Adverse Event 5. Therapeutic Response
outcomes:
Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias
1. Blood Transfusion 2. Quality of Life 3. Adverse Event 4. Haemoglobin level
outcomes:
Laser therapy for retinopathy in sickle cell disease
1. Proliferative Retinopathy Due To Sickle Cell Disease 2. Clinical Improvement
outcomes:
Inhaled bronchodilators for acute chest syndrome in people with sickle cell disease
1. Forced Expiratory Volume 1 2. Forced Vital Capacity 3. All Cause Mortality 4. Peak Flow Rate 5. Death 6. Acute Chest Syndrome 7. Lung function test 8. Adverse Event
outcomes:
Extracorporeal photopheresis versus standard treatment for acute graft‐versus‐host disease after haematopoietic stem cell transplantation in children and adolescents
1. Therapeutic Response
outcomes:
Hydroxyurea (hydroxycarbamide) for sickle cell disease
1. Life-threatening Illness or event 2. Neutrophil Count 3. Pain 4. Opioids 5. Quality of Life 6. Hereditary Persistence Of Fetal Hemoglobin Thalassemia 7. Death 8. Withdrawal Due To Adverse Events 9. Drug toxicity 10. Health Care Utilization
outcomes:
Inhaled nitric oxide for treating pain crises in people with sickle cell disease
1. Duration of Symptom 2. Frequency of symptom 3. Clinical Resolution 4. Adverse Event 5. Time-to-Event 6. Pain Crisis
outcomes:
Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria
1. Serious Adverse Event
outcomes:
Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta‐analysis
1. Death
outcomes:
Extracorporeal photopheresis versus alternative treatment for chronic graft‐versus‐host disease after haematopoietic stem cell transplantation in children and adolescents
1. Therapeutic Response
outcomes:
Indoor residual spraying for preventing malaria in communities using insecticide‐treated nets
1. Malaria 2. Entomological Inoculation Rate 3. Anemia
outcomes:
Angiotensin‐converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease
1. Albumin Human (usp) 2. Urine Protein Test 3. Serum Creatinine 4. Finding Of Urine Electrolyte Levels
outcomes:
Maternal and foetal outcomes following natural vaginal versus caesarean section (c‐section) delivery in women with bleeding disorders and carriers
1. Infant Death 2. Postpartum Hemorrhage 3. Maternal Death
outcomes:
Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay‐Sachs disease
1. Premature Delivery 2. Decision making 3. Pregnancy 4. Reproductive Finding 5. Low Birth Weight Infant 6. Genetic Finding 7. Congenital Malformation
outcomes:
Recombinant growth hormone therapy for X‐linked hypophosphatemia in children
1. Osteocalcin measurement 2. Serum Phosphate 3. Renal function 4. Growth 5. Alkaline phosphatase measurement 6. 1,25-dihydroxyvitamin D measurement 7. Adverse Event 8. Body proportions 9. Serum Insulin-like Growth Factor 1 Measurement 10. Serum Calcium 11. Growth Hormone Measurement
outcomes:
Mass drug administration for malaria
1. Parasitemia 2. Adverse Event
outcomes:
Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI
1. Stair-climbing Test 2. 12-minute Walk Test 3. Functional ability
outcomes:
Chimeric antigen receptor (CAR) T‐cell therapy for people with relapsed or refractory diffuse large B‐cell lymphoma
1. Serious Adverse Event 2. Progression-Free Survival 3. Overall Survival 4. Quality of Life 5. Adverse Event 6. Cytokine-associated Toxicity 7. Complete response
outcomes:
Rituximab for eradicating inhibitors in people with acquired haemophilia A
1. Treatment Success 2. Remission
outcomes:
Clotting factor concentrates for preventing bleeding and bleeding‐related complications in previously treated individuals with haemophilia A or B
1. Orthopedic Joint Score 2. Quality of Life 3. Haemorrhage 4. Adverse Event
outcomes:
Intermittent preventive treatment for malaria in infants
1. All Cause Mortality 2. Malaria 3. Anemia 4. Hospital admission 5. Parasitemia
outcomes:
Hematopoietic stem cell transplantation for people with β‐thalassaemia
1. Event-Free Survival 2. Quality of Life 3. Death 4. Time-to-Event 5. Therapeutic Response
outcomes:
Disease‐modifying treatments for primary autoimmune haemolytic anaemia
1. Complete response 2. Adverse Event
outcomes:
Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease
1. Nausea And Vomiting 2. Antibiotic resistance test 3. Death 4. Pneumococcal Infectious Disease 5. Adverse Event 6. Patient compliance 7. Antibiotic Therapy
outcomes:
Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria
1. Treatment Failure 2. Polymerase Chain Reaction
outcomes:
Interventions for treating leg ulcers in people with sickle cell disease
1. Amputation 2. Quality of Life 3. Evaluation Of Ulcer Healing 4. Wound Healing 5. Adverse Event 6. Survival 7. Time-to-Event
outcomes:
Tyrosine supplementation for phenylketonuria
1. Neuropsychological Testing 2. Blood Tyrosine 3. Weight Gain 4. Finding Of Phenylalanine Level 5. Nutritional status 6. Intelligence
outcomes:
Paediatric formulations of artemisinin‐based combination therapies for treating uncomplicated malaria in children
1. Serious Adverse Event 2. Gastrointestinal findings 3. Polymerase Chain Reaction 4. Drug Tolerance 5. Adverse Event
outcomes:
Gene therapy for sickle cell disease
1. Event-Free Survival 2. Survival
outcomes:
Phytomedicines (medicines derived from plants) for sickle cell disease
1. Employee absenteeism 2. Leg Ulcer 3. Anemia 4. Hospitalization 5. Absenteeism 6. Acute Chest Syndrome 7. Adverse Event 8. Acute Sickle Cell Splenic Sequestration Crisis 9. Blood Transfusion 10. Toxicity Renal 11. Quality of Life 12. Complication 13. Hemoglobin SS Disease 14. Pain Crisis
outcomes:
Rituximab for treating inhibitors in people with inherited severe hemophilia
1. Relapse 2. Treatment Failure 3. Treatment Success
outcomes:
Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease
1. Transfusion Related Complications 2. Stroke 3. All Cause Mortality 4. Serious Adverse Event 5. Neurological Impairment 6. Quality of Life 7. Serum Ferritin Abnormal 8. Alloimmunisation 9. Acute Chest Syndrome 10. Transient Cerebral Ischemia
outcomes:
Dietary interventions for phenylketonuria
1. Neuropsychological Testing 2. Blood Phenylalanine Increased 3. Intelligence Test
outcomes:
Interventions for mycosis fungoides
1. Adverse Event 2. Health-Related Quality of Life 3. Therapeutic Response
outcomes:
Hematopoietic stem cell transplantation for people with sickle cell disease
1. Event-Free Survival
outcomes:
Preoperative blood transfusions for sickle cell disease
1. Infection 2. Cholecystectomy 3. Transfusion Related Complications 4. All Cause Mortality 5. Serious Adverse Event 6. Surgical complication 7. Quality of Life 8. Perioperative Death 9. Death 10. Complication 11. Acute Chest Syndrome 12. Pain Crisis
outcomes:
Interventions for treating intrahepatic cholestasis in people with sickle cell disease
1. All Cause Mortality 2. Serious Adverse Event 3. Treatment Failure 4. Adverse Event
outcomes:
Growth hormone therapy for people with thalassaemia
1. Glucose Tolerance Test 2. Height 3. Height Increased 4. Adverse Event 5. Patient Satisfaction
outcomes:
Vitamin D supplementation for sickle cell disease
1. 25-Hydroxy Vitamin D Analysis 2. Bone Density 3. Pain 4. Acute Chest Syndrome 5. Adverse Event 6. Health-Related Quality of Life 7. Respiratory Tract Infection
outcomes:
Gene therapy for haemophilia
1. Serious Adverse Event 2. Factor IX 3. Coagulation Factor VIII 4. Abnormal Clotting Factor 5. Haemorrhage 6. Tumor Finding 7. Drug toxicity
outcomes:
Interventions for preventing silent cerebral infarcts in people with sickle cell disease
1. Cognitive function 2. All Cause Mortality 3. Stroke 4. Cerebral Infarction 5. Serious Adverse Event 6. Quality of Life 7. Acute Chest Syndrome 8. Pain Crisis
outcomes:
Transcutaneous electrical nerve stimulation (TENS) for pain management in sickle cell disease
1. Activities of Daily Living 2. Analgesia 3. Quality of Life 4. Adverse Event 5. Pain Relief 6. Pain Intensity 7. Pain Crisis
outcomes:
Early erythropoiesis‐stimulating agents in preterm or low birth weight infants
1. Intraventricular Hemorrhage 2. Retinopathy Of Prematurity 3. Enteral nutrition 4. Necrotizing Enterocolitis 5. Periventricular Leukomalacia 6. Death 7. Intelligence Test 8. Red Blood Cell Transfusion 9. Cerebral Palsy 10. Survival 11. Neurodevelopmental Delay
outcomes:
Late erythropoiesis‐stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants
1. All Cause Mortality 2. Retinopathy Of Prematurity 3. Necrotizing Enterocolitis 4. Red Blood Cell Transfusion
outcomes:
Blood transfusions for treating acute chest syndrome in people with sickle cell disease
1. Chest Pain 2. Death 3. Fever
outcomes:
Intravenous iron therapy for non‐anaemic, iron‐deficient adults
1. Quality of Life 2. Hemoglobin concentration
outcomes:
Treatment of dental complications in sickle cell disease
1. Pain 2. Tooth Finding 3. Visual Analog Scale 4. Clinical Resolution
outcomes:
Treatment for avascular necrosis of bone in people with sickle cell disease
1. Infection 2. Intraoperative Hemorrhage 3. Prosthetic Joint Loosening 4. Pain 5. Analgesics 6. Death 7. Complication 8. Hemoglobin SS Disease With Vasoocclusive Crisis 9. Acute Chest Syndrome 10. Fracture 11. Adverse Event 12. Hemoglobin SS Disease
outcomes:
Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use undergoing non‐cardiac surgery or invasive procedures
1. All Cause Mortality 2. Hemostatic agent 3. Serious Adverse Event 4. Transfusion 5. Coagulation Test 6. Decreased Blood Volume 7. Duration Of Hospital Stay 8. Thromboembolism
outcomes:
Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults with transplant‐ineligible multiple myeloma: a network meta‐analysis
1. European Organization For Research And Treatment Of Cancer - Quality Of Life Questionnaire 2. Progression-Free Survival 3. Overall Survival 4. Adverse Event
outcomes:
Pharmacological interventions for painful sickle cell vaso‐occlusive crises in adults
1. Serious Adverse Event 2. Patient Global Impression of Change 3. Withdrawal Due To Adverse Events 4. Adverse Event 5. Pain Relief 6. Patient-Reported Outcome
outcomes:
Statins for children with familial hypercholesterolemia
1. Puberty Stage 2. Impaired Liver Function 3. Growth 4. Carotid Artery Finding 5. Disorder Of Muscle 6. Endothelial function 7. Low Density Lipoprotein Cholesterol Measurement 8. Adverse Event
outcomes:
Regular long‐term red blood cell transfusions for managing chronic chest complications in sickle cell disease
1. Transfusion Related Complications 2. Chronic Lung Disease 3. Death 4. Pulmonary Hypertension 5. Acute Chest Syndrome
outcomes:
Antibiotics for treating osteomyelitis in people with sickle cell disease
1. Clinical Resolution 2. Time-to-Event
outcomes:
Splenectomy for people with thalassaemia major or intermedia
1. Postoperative Hemorrhage 2. Intraoperative Hemorrhage 3. Ferritin level 4. Serious Adverse Event 5. Transfusion 6. Postoperative Atelectasis 7. Quality of Life 8. Haematology Investigations 9. Duration Of Hospital Stay 10. Adverse Event
outcomes:
Magnesium for treating sickle cell disease
1. Headache 2. Infusion site warmth 3. Serious Adverse Event 4. Red Blood Cell Finding 5. Quality of Life 6. Diarrhea 7. Length Of Stay 8. Low Blood Pressure 9. Adverse Event 10. Health-Related Quality of Life 11. Pain Crisis
outcomes:
Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions
1. Postoperative Hemorrhage 2. Bleeding From Mouth 3. Adverse Drug Reaction 4. Adverse Event
outcomes:
Hydroxyurea (hydroxycarbamide) for transfusion‐dependent β‐thalassaemia
1. Blood Transfusion 2. Hemoglobin concentration
outcomes:
Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders
1. Infant Death 2. Postpartum Hemorrhage 3. Maternal Death
outcomes:
Aerobic physical exercise for adult patients with haematological malignancies
1. Quality of Life
outcomes:
Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft‐versus‐host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition
1. All Cause Mortality 2. Relapse 3. Infusion related reaction 4. Acute Graft-versus-host Disease 5. Complete response 6. Health-Related Quality of Life 7. Chronic Graft-versus-host Disease
outcomes:
Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia resolution in people with cancer
1. Death
outcomes:
Pro‐coagulant haemostatic factors for the prevention and treatment of bleeding in people without haemophilia
1. All Cause Mortality 2. Arterial Thrombosis 3. Venous Thrombosis
outcomes:
Vaccines for preventing invasive salmonella infections in people with sickle cell disease
1. Salmonella Infection 2. Morbidity Index 3. Death
outcomes:
Insecticide‐treated nets for preventing malaria
1. All Cause Mortality 2. Malaria 3. Anemia 4. Vivax Malaria 5. Plasmodium Falciparum Infection 6. Plasmodium Vivax Malaria With Rupture Of Spleen 7. Plasmodium Species - Unable To Speciate
outcomes:
Drugs for preventing red blood cell dehydration in people with sickle cell disease
1. Employee absenteeism 2. Red Blood Cell Finding 3. Quality of Life 4. Death 5. Complication 6. Sickle Cell Crisis 7. Dehydration 8. Hemoglobin SS Disease
outcomes:
Prophylactic platelet transfusions prior to surgery for people with a low platelet count
1. Death 2. Haemorrhage
outcomes:
Conjugate Haemophilus influenzae type b vaccines for sickle cell disease
1. Morbidity Index 2. Death 3. Haemophilus Influenzae Type B Infection
outcomes:
Effects of all‐trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (non‐APL))
1. Infection 2. Vomiting 3. Overall Survival 4. Quality of Life 5. Death 6. Diarrhoea 7. Nausea
outcomes:
Comparison of a therapeutic‐only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders
1. Haemorrhage
outcomes:
Folate supplementation in people with sickle cell disease
1. Infection 2. Folic Acid 3. Priapism 4. Dactylitis 5. Pain 6. Cobalamin Deficiency 7. Adverse Event 8. Acute Sickle Cell Splenic Sequestration Crisis 9. Hemoglobin concentration
outcomes:
Mosquito repellents for malaria prevention
1. Malaria 2. Vivax Malaria 3. Plasmodium Falciparum Infection 4. Parasitemia